文献速递骨质疏松与钙磷/甲状旁腺

骨质疏松治疗转换的患者管理策略

Approach to the Patient - Transitions in Osteoporosis Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

本文综述了骨质疏松症目标导向治疗策略中治疗转换的机遇与挑战。从骨合成代谢治疗转换至抗骨吸收治疗可维持或进一步提高骨密度及抗骨折效果;抗骨吸收药物间转换多数安全;但从抗骨吸收药物转换为骨合成代谢治疗会削弱合成效应,且停用狄诺塞麦2-3年后需警惕。多数转换安全,但应避免从狄诺塞麦转换为骨合成代谢药或无适当后续治疗的狄诺塞麦停药。

要点

  • 骨合成代谢治疗转抗骨吸收治疗可维持或提升骨密度及抗骨折效果。
  • 口服抗骨吸收药转静脉唑来膦酸或狄诺塞麦可能进一步增加骨密度。
  • 避免狄诺塞麦转骨合成代谢药或无后续治疗的狄诺塞麦停药。

核心结论

  • 多数骨质疏松治疗转换是安全的,但应避免从狄诺塞麦转换为骨合成代谢药物或无适当后续治疗的狄诺塞麦停药。

研究设计与样本

  • 本文为综述,讨论骨质疏松治疗转换的策略与挑战。

主要发现

  • 从骨合成代谢治疗转换为抗骨吸收治疗可维持或进一步提高骨密度及抗骨折效果。
  • 从一种抗骨吸收药物转换为另一种多数安全,口服转静脉唑来膦酸或狄诺塞麦可能进一步增加骨密度。
  • 从抗骨吸收药物转换为骨合成代谢治疗时合成效应较未治疗患者减弱。
  • 停用狄诺塞麦超过2至3年后转换或停药存在挑战。

关键数值与推荐

  • 避免从狄诺塞麦转换为骨合成代谢药物。
  • 避免停用狄诺塞麦而无适当后续治疗。

临床怎么用

  • 对多数患者需序贯治疗以预防骨折并达到可接受骨折风险的骨密度水平。
  • 转换治疗时应避免从狄诺塞麦转为骨合成代谢药或无后续治疗的停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Moving toward a goal-directed-treatment strategy in osteoporosis necessitates considering the opportunities and challenges associated with transitions in osteoporosis therapy. Some transitions are straightforward; transition from bone anabolic treatment to antiresorptives maintains or further improves the bone mineral density (BMD) increase and the antifracture effect obtained during treatment with a bone anabolic. Transitions from one antiresorptive to another are also, in most cases, safe and may lead to further increases in BMD if the transition is from an oral antiresorptive to a parentally administrated antiresorptive, such as zoledronate or denosumab. However, challenges arise when transitioning from antiresorptives to bone anabolic treatment, as the anabolic effect will be blunted compared to the effect seen in treatment-naïve patients, and transitions involving discontinuation of denosumab after more than 2 to 3 years of treatment. Sequential treatment of osteoporosis is needed for many patients to prevent fractures and obtain BMD levels associated with an acceptable fracture risk. While not all treatment transitions are optimal, the majority are safe, except for transitioning from denosumab to a bone anabolic agent or discontinuation of denosumab without appropriate follow-up treatment. These specific transitions should be avoided.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Langdahl BL, Laursen NA, Mäkinen V, et al. Approach to the Patient - Transitions in Osteoporosis Therapy. J Clin Endocrinol Metab. 2026. PMID: 41243689. doi:10.1210/clinem/dgaf614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。